Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aktis Oncology, Inc. filings document the company’s transition into a Nasdaq-listed public oncology issuer and its disclosure obligations as a clinical-stage oncology company. S-1/A registration materials and current reports describe its targeted radiopharmaceutical pipeline, including AKY-1189 and AKY-2519, the miniprotein radioconjugate platform, collaboration revenue, and operating results.
Its filings also cover post-IPO governance and capital-structure matters, including amended charter provisions, authorized common, Class A common and undesignated preferred stock, classified board provisions, director appointments, board committee structure, financial-results exhibits, and registered common stock under the AKTS symbol.
Aktis Oncology, Inc. filed an initial Form 3 showing that its Chief Scientific Officer, Paul L. Feldman, beneficially owns 144,568 shares of common stock directly as of January 8, 2026.
He also holds several stock options to buy common stock: one option for 65,713 shares at an exercise price of $1.91 per share expiring on April 14, 2031, which has vested in full; an option for 119,248 shares at $3.66 per share expiring on November 15, 2032 that vests monthly after 25% vested on November 1, 2023; an option for 90,684 shares at $9.33 per share expiring on October 10, 2034 with similar monthly vesting after 25% vested on October 9, 2025; and an option for 131,246 shares at $18 per share expiring on January 7, 2036, with 25% scheduled to vest on January 8, 2027 and the remainder in monthly installments, all subject to his continuous service.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere filed an initial ownership report showing holdings of several stock options. These options give rights to buy common stock at exercise prices of $4.95 for 271,218 shares, $9.33 for 98,570 shares, $11.46 for 19,714 shares, and $18.00 for 131,426 shares, all held directly. Portions of the earlier grants vested on July 1, 2025 and October 9, 2025, with the remaining shares vesting in equal monthly installments, subject to continued service. Newer grants are scheduled to begin vesting with 25% cliffs on November 1, 2026 and January 8, 2027, followed by monthly vesting thereafter.
Aktis Oncology director Michael A. Sherman filed a report of his beneficial ownership of stock options in Aktis Oncology, Inc. On January 8, 2026, he held a stock option for 74,913 shares of common stock at an exercise price of $9.14, expiring on October 8, 2035. Twenty‑five percent of these shares vest on August 1, 2026, with the remainder vesting in equal monthly installments, subject to his continued service. He also held a second stock option for 18,933 shares at an exercise price of $18, expiring on January 7, 2036, which vests in full on January 8, 2027 if he remains in service.
Aktis Oncology, Inc. director Mary Thistle filed an initial ownership report showing she beneficially owns two stock option awards for common stock as of January 8, 2026. One option covers 74,913 shares at an exercise price of $10.66 per share, expiring on January 14, 2035. The filing notes that 25% of this option vests on January 15, 2026, with the remainder vesting in equal monthly installments thereafter, subject to continued service. A second option covers 18,933 shares at an exercise price of $18 per share, expiring on January 7, 2036, and is scheduled to vest in full on January 8, 2027, also conditioned on her continuous service.
Aktis Oncology, Inc. (AKTS) filed a Form 3 for EcoR1 Capital, LLC and Oleg Nodelman, identifying them as a director and 10% owners. The filing reports indirect beneficial ownership of Series A and Series B redeemable convertible preferred stock held through EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P., and EcoR1 Venture Opportunity Fund, L.P. These preferred shares are immediately exercisable, have no expiration date, and will automatically convert into common stock on a 3.8044-for-1 basis immediately before the closing of the company’s initial public offering, with amounts reflecting a 1-for-3.8044 reverse stock split effective January 2, 2026.
The Form 3 also discloses a director stock option for 37,866 shares of common stock at an exercise price of $18, beneficially owned solely by Mr. Nodelman. One‑thirty‑sixth of the option vests in monthly installments from January 8, 2026, subject to his continuous service. The reporting persons are filing jointly, but state they are not a group and disclaim beneficial ownership of the securities except to the extent of their pecuniary interests.
Vida Ventures II, LLC and Vida Ventures II-A, LLC filed an initial Form 3 as 10% owners of Aktis Oncology, Inc. (AKTS), reporting indirect holdings of the company’s preferred stock. The filing shows Series A and Series B Redeemable Convertible Preferred Stock that each convert into common stock on a 3.8044-for-1 basis with no expiration date. All shares of both preferred series will automatically convert into common stock immediately prior to the closing of Aktis Oncology’s initial public offering, without any additional payment. The shares are held through Vida Ventures II and Vida Ventures II-A, with management entities and committee members disclaiming beneficial ownership beyond their pecuniary interest.
Aktis Oncology, Inc. is offering 17,650,000 shares of common stock in an initial public offering, with an expected price range of $16.00 to $18.00 per share and a 30‑day underwriters’ option for up to 2,647,500 additional shares. The company expects about $274.5 million in net proceeds at a $17.00 midpoint, and 52,522,279 shares of common stock outstanding after the deal. Aktis is a clinical-stage radiopharmaceutical company developing miniprotein-based drugs targeting solid tumors, led by Nectin‑4 candidate [225Ac]Ac‑AKY‑1189 in a Phase 1b trial and B7‑H3 program [225Ac]Ac‑AKY‑2519 nearing an IND filing. Eli Lilly has indicated interest in purchasing approximately $100.0 million of stock in the IPO and previously paid $60.0 million upfront plus an equity investment in a discovery collaboration with milestones up to $1.2 billion. Aktis reported net losses of $44.0 million in 2024 and $48.6 million for the nine months ended September 30, 2025, with an accumulated deficit of $141.4 million and $246.2 million in cash, cash equivalents and marketable securities, which it believes will fund operations into 2029.